Tango Therapeutics, Inc. (TNGX) Income Statement
TNGX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsTNGX revenue and net income
Where TNGX's revenue goes
2025Each bar shows an amount and its share of revenue. TNGX kept −162.9% of revenue as net income.
TNGX profit margins
TNGX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +48.3% | +35.9% | +52.1% | — |
| Gross profit | +42.9% | +34.2% | +58.4% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
TNGX quarterly EPS vs estimates
Tango Therapeutics beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 3, 2026 (estimate $-0.34).
TNGX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $62.4M | $42.1M | $36.5M | $24.9M | $37.0M | $7.7M | $24.6M |
| Cost of revenue | $2.3M | $2.5M | $115.2M | $4.0M | $2.0M | $1.6M | $32.3M |
| Gross profit | $60.1M | $42.1M | $36.5M | $24.9M | $37.0M | $6.0M | −$7.6M |
| Research & development | $132.2M | $143.9M | $115.2M | $105.9M | $77.6M | $50.0M | $32.3M |
| Sales, general & admin | $41.5M | $43.7M | $35.5M | $30.0M | $17.6M | $9.9M | $7.5M |
| Total operating expenses | $171.4M | $187.7M | $150.7M | $135.9M | $95.2M | $58.2M | $7.5M |
| Operating income | −$111.3M | −$145.6M | −$114.2M | −$111.1M | −$58.2M | −$52.2M | −$15.2M |
| Interest income | $5.6M | $7.9M | $5.0M | $1.5M | $495,000 | $108,000 | — |
| Interest expense | — | — | — | $2.9M | $1.1M | $0 | $0 |
| Income before taxes | −$101.6M | −$130.1M | −$101.6M | −$108.1M | −$57.9M | −$52.0M | −$14.1M |
| Income taxes | $4,000 | $208,000 | $134,000 | $54,000 | $292,000 | −$108,000 | — |
| Net income | −$101.6M | −$130.3M | −$101.7M | −$108.2M | −$58.2M | −$52.0M | −$14.1M |
| EBITDA | −$99.3M | −$127.6M | −$99.2M | −$109.5M | −$57.3M | −$50.3M | −$14.5M |
| EPS (diluted) | −$0.87 | −$1.20 | −$1.10 | −$1.23 | −$0.70 | −$0.01 | — |
| Gross margin | 96.3% | 100.0% | 100.0% | 100.0% | 100.0% | 78.8% | −30.9% |
| Operating margin | −178.4% | −346.1% | −312.6% | −446.8% | −157.1% | −681.8% | −61.5% |
| Net margin | −162.9% | −309.7% | −278.5% | −435.1% | −157.2% | −678.8% | −57.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $53.8M | $3.2M | $5.4M | $4.1M | $11.6M | $19.9M | $6.5M | $5.4M | $10.7M |
| Cost of revenue | — | $463,000 | $479,000 | $555,000 | $625,000 | $0 | $620,000 | $0 | $632,000 | $625,000 | $617,000 | $613,000 |
| Gross profit | — | −$463,000 | −$479,000 | $53.8M | $2.6M | $5.4M | $4.1M | $11.6M | $19.9M | $6.5M | $5.4M | $10.1M |
| Research & development | $37.2M | $33.1M | $33.3M | $30.8M | $32.2M | $36.4M | $33.9M | $33.3M | $38.7M | $38.1M | $31.3M | $27.1M |
| Sales, general & admin | $22.6M | $15.2M | $9.8M | $8.9M | $11.3M | $11.5M | $11.1M | $11.2M | $11.4M | $11.3M | $9.1M | $9.2M |
| Total operating expenses | $59.8M | $48.3M | $41.4M | $39.7M | $43.5M | $47.9M | $45.0M | $44.5M | $49.4M | $48.7M | $40.4M | $35.7M |
| Operating income | −$59.8M | −$48.8M | −$41.9M | $14.1M | −$41.0M | −$42.5M | −$40.9M | −$32.9M | −$29.6M | −$42.3M | −$35.0M | −$25.6M |
| Interest income | $3.7M | $2.2M | $1.7M | $1.1M | $1.2M | $1.6M | $1.8M | $1.8M | $2.1M | $2.2M | $2.2M | $1.9M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $581,000 | — |
| Income before taxes | −$55.3M | −$45.5M | −$38.8M | $15.9M | −$38.8M | −$39.8M | −$37.6M | −$29.1M | −$25.5M | −$37.9M | −$30.7M | −$22.2M |
| Income taxes | $1,000 | $1,000 | −$55,000 | −$10,000 | $35,000 | $34,000 | $49,000 | $54,000 | $65,000 | $40,000 | $47,000 | $23,000 |
| Net income | −$55.3M | −$45.5M | −$38.7M | $15.9M | −$38.9M | −$39.9M | −$37.7M | −$29.2M | −$25.6M | −$37.9M | −$30.8M | −$22.3M |
| EBITDA | −$54.9M | −$45.0M | −$38.3M | $16.4M | −$38.2M | −$39.2M | −$37.0M | −$28.5M | −$24.9M | −$37.2M | −$30.1M | −$21.6M |
| EPS (diluted) | −$0.37 | −$0.32 | −$0.29 | $0.13 | −$0.35 | −$0.36 | −$0.34 | −$0.27 | −$0.24 | −$0.35 | −$0.32 | −$0.23 |
| Gross margin | — | — | — | 100.0% | 80.4% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 94.3% |
| Operating margin | — | — | — | 26.2% | −1,287.9% | −788.8% | −993.7% | −283.3% | −148.7% | −653.0% | −644.7% | −238.8% |
| Net margin | — | — | — | 29.5% | −1,221.4% | −739.5% | −915.0% | −251.3% | −128.6% | −585.9% | −566.4% | −207.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in TNGX's financial statements (latest annual report filed March 5, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
TNGX financial results
In fiscal year 2025 (ended December 31, 2025), Tango Therapeutics reported revenue of $62.4 million, up 48.3% from the year before. It had a net loss of $101.6 million, a net profit margin of −162.9%. Diluted earnings per share came to −$0.87. Over five years revenue grew at an average rate of 52.1% a year.
See the TNGX stock overview for the latest quote and news, or the TNGX chart for price history and technical indicators.
TNGX income statement FAQ
What is Tango Therapeutics's annual revenue?
Tango Therapeutics reported total revenue of $62.4 million for fiscal year 2025, which ended on December 31, 2025. That was up 48.3% from $42.1 million the previous year.
Is Tango Therapeutics profitable?
No. Tango Therapeutics reported a net loss of $101.6 million in fiscal 2025, a net profit margin of −162.9%; its operating margin was −178.4%.
What is Tango Therapeutics's gross margin?
Tango Therapeutics's gross margin was 96.3% in fiscal 2025: for every $100 of revenue, Tango Therapeutics kept $96 after the direct cost of its products and services.
How much does Tango Therapeutics spend on research and development?
Tango Therapeutics spent $132.2 million on research and development in fiscal 2025, 211.9% of revenue.
How fast is Tango Therapeutics growing?
Revenue grew 52.1% a year on average over the last five fiscal years, from $7.7 million to $62.4 million.
What are Tango Therapeutics's earnings per share?
Tango Therapeutics earned $-0.87 per diluted share in fiscal 2025, compared with $-1.20 a year earlier.
When will Tango Therapeutics report its next earnings?
Tango Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 3, 2026.
When does Tango Therapeutics's fiscal year end?
Tango Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 5, 2026.